Background
Phase III open-label randomized trial. N=518 (261 palbociclib, 257 standard) with HR+/HER2+ metastatic breast cancer and no progression after 4–8 cycles of induction chemotherapy + HER2-targeted therapy.
Interventions and follow up
Arm A: Palbociclib + trastuzumab/pertuzumab + endocrine therapy maintenance
Arm B: Trastuzumab/pertuzumab + endocrine therapy (standard)
Primary endpoint: Progression-free survival (PFS)
mFollow up: 53.5mo
Arm B: Trastuzumab/pertuzumab + endocrine therapy (standard)
Primary endpoint: Progression-free survival (PFS)
mFollow up: 53.5mo
Results
PFS: 44.3 vs 29.1mo (15.2mo improvement), HR 0.75, 95% CI 0.59–0.96, P=.02
OS: immature at primary PFS analysis
QoL: maintained despite increased hematologic toxicity
OS: immature at primary PFS analysis
QoL: maintained despite increased hematologic toxicity
Adverse events
Overall (grade 3–4, palbociclib vs standard): 79.7% vs 30.6%
Hematologic (palbociclib): neutropenia (dominant); thrombocytopenia; grade 4 events 10.0%
Management: manageable with dose modifications
Hematologic (palbociclib): neutropenia (dominant); thrombocytopenia; grade 4 events 10.0%
Management: manageable with dose modifications
Conclusions
Adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improved PFS (15+ months) in HR+/HER2+ MBC, consolidating the CDK4/6 inhibitor role in luminal HER2+ disease. QoL was maintained despite increased hematologic toxicity.
Key Limitations
OS immature at primary PFS analysis; open-label design may introduce bias; limited generalizability to non-luminal HER2+ subtypes; high hematologic toxicity burden may limit tolerability in some patients.
Clinical Context
PATINA establishes a CDK4/6 inhibitor role in HR+/HER2+ MBC as maintenance after induction chemotherapy, offering a chemotherapy-free option. Supports ASCO guidance for luminal HER2+ sequencing; FDA review anticipated. ESMO-MCBS pending.
References